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Abstract
Background: Depressive symptoms and decreased physical functioning are interrelated conditions and common in
older persons, causing significant individual and societal burden. Evidence suggests that vitamin D supplementation
may be beneficial for both mental and physical functioning. However, previous randomized controlled trials
have yielded inconsistent results and often had suboptimal designs. This study examines the effect of vitamin D
supplementation on both depressive symptoms and physical functioning in a high-risk population of older persons
with low vitamin D status.
Methods/design: The D-Vitaal study is a randomized, double-blind, placebo-controlled trial investigating the effects of
a daily dose of 1200 IU vitamin D3 versus placebo for one year on depressive symptoms and physical functioning
(primary outcomes) in older adults. Participants (N = 155, age 60–80 years) were recruited from the general population.
Eligibility criteria included the presence of depressive symptoms, ≥1 functional limitation and serum 25-hydroxyvitamin
D levels between 15 and 50/70 nmol/L (depending on season). Secondary outcomes include incidence of major
depressive disorder, anxiety symptoms, health-related quality of life, cognitive function and cost-effectiveness of the
intervention.
Discussion: With this study, we aim to elucidate the effects of vitamin D supplementation on depressive symptoms
and physical functioning in older persons who are at high risk of developing more substantial mental and physical
problems. If effective, vitamin D supplementation can be a preventive intervention strategy that is easy to implement
in the primary care setting.
Trial registration: Netherlands Trial Register NTR3845. Registered 6 February 2013.
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Background
Depressive symptoms are common in older adults, occur-
ring in 8-16 % of persons over 55 years of age [1]. These
symptoms are associated with various adverse health out-
comes, such as a higher risk of cardiovascular diseases
[2], hospitalization and mortality [3] and reduced quality
of life [1]. Treatment of depression in older persons is
often suboptimal, for example due to societal stigma,
side-effects of anti-depressant medication, or interactions
of antidepressants with other medications [2, 4]. Hence,
development of a simple and safe prevention strategy is
pivotal.
Ageing is also commonly accompanied by a decline of
physical functioning. Studies show that functional limita-
tions and poor physical performance are highly interre-
lated with depressive symptoms, both cross-sectionally
and longitudinally [2, 5–9], which can easily result in a
downward spiral.
Previous research suggests that vitamin D supplemen-
tation may improve both mental and physical health,
although evidence is inconsistent [10–12]. Vitamin D
inadequacy - defined as serum 25-hydroxyvitamin D
(25(OH)D) levels of <50 nmol/L [13] - occurs in about
50 % of elderly persons from Western countries [14].
Vitamin D is synthesized in the skin under the influence
of sunlight. In addition, some vitamin D is retrieved from
food, especially from fatty fish [15]. Causes of vitamin D
deficiency in older persons include declining efficiency of
the skin to synthesize vitamin D, a lower amount of sun
exposure and reduced nutritional intake [16].
Several biological mechanisms that can explain the re-
lationship of vitamin D deficiency with depressive symp-
toms and poor physical functioning have been suggested
(see also Fig. 1). The active metabolite of vitamin D -
1,25 dihydroxyvitamin D (1,25(OH)2D) - is synthesized
in the brain by the enzyme 1α-hydroxylase [17], enabling
local activation of vitamin D. Moreover, the vitamin D
receptor (VDR) is present in several brain areas import-
ant for depression and emotional behaviour, including
the hippocampus and hypothalamus [18]. Furthermore,
1,25(OH)2D promotes the synthesis of depression-related
monoamine neurotransmitters such as serotonin [17, 19, 20]
and has a general protective effect on brain functioning
through immunomodulation, anti-inflammatory action
and promotion of neuroplasticity [17, 19, 21]. Regarding
physical functioning, the VDR has been observed in the
cerebellum [18], which is an important brain area for
mobility, gait and balance [22]. In addition, the presence
of 1,25(OH)2D and the VDR in muscle tissue facili-
tates muscle contraction speed, muscle power and cell
growth [19].
Prospective cohort studies suggest that vitamin D defi-
ciency is associated with depressive symptoms, poor
physical performance and functional limitations [23–26].
In the InChianti study, vitamin D deficiency at baseline
almost doubled the risk of depressive symptoms after
three and six years and was also associated with lower
physical performance [27].
Evidence from randomized controlled trials (RCTs) is
diffuse and inconclusive. Tables 1 and 2 provide an over-
view of previous RCTs examining the effects of vitamin
D supplementation on depressive symptoms and physical
functioning. Only RCTs that included adults and had a
sample size of ≥40 were selected (search strategy avail-
able from the author). From these tables, it can be con-
cluded that previous RCTs have been heterogeneous
with respect to sample size, age range of the partici-
pants, dosage of the supplementation, duration of the
intervention and outcome measures. Moreover, only a
very limited amount of studies included high-risk par-
ticipants, i.e. persons with low serum 25(OH)D and
mental/physical symptoms at baseline. It can be ex-
pected that supplementation is more effective and rele-
vant in persons with low baseline 25(OH)D levels and
Fig. 1 Pathophysiological effects of low vitamin D status on mental and physical functioning
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Table 1 Overview of RCTs that examined the effect of vitamin D supplementation on depression





Lansdowne et al., 1998 [68] 44 healthy adults, age
18–43 yrs., 77 % female.
No No 400 or 800 IU/day vitD3 vs.
placebo for 5 days in late
winter.




affect in both vitD groups.
Jorde et al., 2008 [69] 441 overweight/obese
outpatients or community
dwellers, age 21–70 yrs.,
64 % female.
No No 20,000 or 40,000 IU/week
vitD3 vs. placebo for 1 yr.
Depressive symptoms (BDI). Lower depression scores in
both vitD groups. Effect
more pronounced in
persons with higher baseline
depression scores.
Sanders et al., 2011 [70] 2012 community dwelling
women, age 70+ yrs.




SF-12, WHO Well-Being index.
NS.
Dean et al., 2011 [71] 128 healthy adults, age
18–30 yrs., 57 % female.
No No 5000 IU/day vitD3 vs.
placebo for 6 weeks.




women, age 50–79 yrs.
No No 400 IU/day vitD3 +
1000 mg/day calcium vs.





Yalamanchiliet al., 2012 [73] 412 post-menopausal
women, age 65–77 yrs.
No No Calcitriol 0.25 g twice daily
vs. placebo + estrogens vs.
placebo for 3 yrs.
Depressive symptoms (GDS). NS.
Khoraminya et al., 2012 [28] 40 outpatients with MDD,
age 18–65 yrs., 85 % female.
No Yes: MDD diagnosis. 1500 IU/day vitD3 + 20 mg
fluoxetine vs. fluoxetine
alone for 8 weeks.
Depression severity (HDRS),
depressive symptoms (BDI).
Vitamin D + fluoxetine
superior to fluoxetine alone
in reducing depressive
symptoms.
Kjærgaard et al., 2012 [29] 230 community dwellers,
age 30–75 yrs., 56 % female.
Yes: 25(OH)D
<55 nmol/L.
No 40,000 IU/week vitD3 vs




Studies published after commencement of the D-Vitaal trial:
Mozaffari- Khosravi et al.,
2013 [30]
109 psychiatric outpatients,
age 20–60 yrs., 72 % female.
Yes: 25(OH)D
< 40 nmol/L.
Yes: BDI score ≥17. Single dose of 150,000 or





symptoms in 300,000 IU
group.
Systematic review of RCTs (inception - July 2015). Search strategy available from author. NS: not significant
PANAS: Positive And Negative Affect Schedule; BDI: Beck Depression Inventory; GHQ: General Health Questionnaire; SF-12: Short Form health survey – 12 item version; MDD: major depressive disorder; GDS: Geriatric













Table 2 Overview of RCTs that examined the effect of vitamin D supplementation on physical functioning








age 70+ yrs., 54 % female.
No No 0.25 μg 1,25(OH)2D3 twice daily
vs. placebo for 6 months.




females, age 70+ yrs.
Yes: 25(OH)D
<50 nmol/L.
No 800 IU/day vitD3 + 1200 mg/day
calcium vs. calcium alone for
8 weeks.




females, age 63–99 yrs.
No No 800 IU/day vitD3 + 1200 mg/day
calcium vs. calcium alone for
12 weeks.
Musculoskeletal function
(knee muscle strength, grip
strength, TUG).
Improved musculoskeletal




males, age 65–87 yrs.
No No 1000 IU/day vitD3 + 500 mg/day
calcium vs. calcium alone for
6 months.







243 geriatric in- and
outpatients, age 65+ yrs.,
53 % female.
No Yes: frailty. Single dose of 300,000 IU vitD2
vs. placebo + exercise training
vs. social visits for 10 weeks.
Physical performance (knee
strength, balance, TUG, gait




139 outpatients, age 65+
yrs., 78 % female.
Yes: 25(OH)D
<30 nmol/L.
Yes: history of falls. Single intramuscular injection
of 600,000 IU vitD2 vs. placebo.
Postural sway, physical
performance (gait speed,




and sway in vitD group.
Gallagher, 2004 [79] 289 postmenopausal
females, mean age 72 yrs.
No No 0.5 μg/day calcitriol vs. placebo
+ estrogen / progesterone
treatment vs. placebo for 3 yrs.
Physical performance (grip
strength, gait speed, chair
stands).
Improved chair stands and gait
speed in vitD group (p < .1).
Sato et al., 2005 [80] 96 females with post-
stroke hemiplegia, mean
age 74 yrs.
No No 1000 IU/day vitD2 vs. placebo
for 2 yrs.
Muscle strength (of the
intact hip).





females, age 65–97 yrs.
No No 800 IU vitD3 + 1200 mg/day








age 70+ yrs., 88 % female.
Yes: 25(OH)D
<40 nmol/L.
No 400 IU/day vitD3 + 800 mg/day
calcium vs. calcium alone +
exercise training vs. control for
9 months.
Muscle strength (quadriceps,
hand grip), gait speed,
physical performance (SPPB,
TUG), postural sway.





persons, mean age 82 yrs.,
65 % female.






females, age 50–79 yrs.
No No 400 IU/day vitD3 + 1000 mg/day
calcium vs. placebo for 5 yrs.






patients, age 62–94 yrs.,
79 % female.
No No 150,000 IU/month vitD3 for
2 months, followed by 90,000
IU/month vs. placebo for
4 months + . 1000 mg/day
calcium.
Lower limb muscle strength
(hip, knee).
Improved lower limb muscle






















No 800 IU/day vitD3 + 1000 mg/day










females, age 65+ yrs.
Yes: hypovitaminosis
D (range NR)
No 0.5 mg/day alfacalcidol + 1500
mg/day calcium vs. calcium
alone for 12 weeks.
Muscle strength (quadriceps). Improved quadriceps muscle




outpatients, age 65+ yrs.
Yes: 25(OH)D
20–50 nmol/L.
No 400 IU/day vitD3 + 500 mg/day
calcium vs. calcium alone for
6 months.
Muscle strength (knee, leg,
hand grip), mobility (TUG),
gait speed.
NS.
Lips et al., 2010 [89] 226 community dwellers,
age 70+ yrs., % female NR.
Yes: 25(OH)D
15–50 nmol/L.
No 8400 IU/week vitD3 vs. placebo
for 16 weeks.
Postural sway, SPPB. Reduced sway in vitD group,




105 patients with systolic




No 100,000 IU vitD2 vs. placebo at
baseline and after 10 weeks.
Gait speed, mobility (TUG),
functional limitations.
NS.
Zhu et al., 2010 [91] 261 community dwelling
females, age 70–90 yrs.
Yes: 25(OH)D
<60 nmol/L.
No VitD2 1000 IU/day + 1000
mg/day calcium vs. calcium
alone for 1 yr.
Lower limb muscle strength
(ankle, knee, hip), mobility
(TUG).
Improved hip muscle strength
and mobility in vitD group,





females, age 70+ yrs.
No No 150,000 IU vitD3 vs. placebo at
baseline and after 3 and
6 months.
Grip strength, mobility (TUG). NS.
Hornikx et al.,
2012 [93]
49 COPD patients, age
50+ yrs., 24 % female.
No No 100,000 IU vitD3/month vs.










patients, age 21–50 yrs.,
71 % female.
No No 20,000 IU vitD3/week vs.
placebo for 2 yrs.
Grip strength. NS.
Studies published after commencement of the D-Vitaal trial:
Hara et al., 2013 [95] 94 postmenopausal
females with osteoporosis,
age 55–75 yrs.
No No 1 μg/day alfacalcidol + 200
mg/day calcium + 35 mg/week
alendronate vs. calcium and
alendronate alone for 4 months.
Muscle strength (back
extensor).
Improved back extensor strength
in younger vitD subgroup.
McAlindon et al.,
2013 [96]
146 adults with knee
osteoarthritis (OA), age
45+ yrs., 61 % female.
No Yes: presence of
symptomatic knee
osteoarthritis.
2000 IU/day vitD3 with dose
escalation to obtain serum levels
of >90 nmol/L vs. placebo for
2 yrs.
Gait speed, chair stands. NS.
Sanghi et al.,
2013 [97]
103 adults with knee
osteoarthritis, age 40–74
yrs., 64 % female.
No Yes: presence of
symptomatic knee
osteoarthritis.
60,000 IU/day vitD3 for 10 days
followed by 60,000 IU/month
vs. placebo for 12 months.
Functional limitations
(WOMAC).
Small improvement of physical

















immigrants, age 18–50 yrs.,
73 % female.
No No 1000 or 400 IU vitD3/day vs.
placebo for 16 weeks.
Grip strength, chair stands,





females, age 60–70 yrs.
No No 400 or 1000 IU/day vitD3 vs.




46 patients with primary
hyperparathyroidism, age
29–77 yrs., 76 % female.
Yes, 25(OH)D
<80 nmol/L.
No 2800 IU/day vitD3 vs. placebo
for 12 months.
Muscle strength (knee, elbow,
hand grip), chair stands,
mobility (TUG), postural sway.
NS.
Systematic review of RCTs (inception - July 2015). Search strategy available from author. NS: not significant. NR: not reported.














in persons with clinically relevant depressive symptoms
or reduced physical functioning.
Four out of nine RCTs on depression (44 %) observed
a significant positive effect of vitamin D supplementation
on depressive symptoms (see Table 1). However, only two
studies included persons with either low 25(OH)D or de-
pression at baseline [28, 29], and only one study included
persons with both characteristics [30]. The latter study
and the study that included persons with a diagnosis of
major depressive disorder (MDD) [28] observed signifi-
cant improvements after the supplementation.
Table 2 shows that in 14 out of 28 RCTs (50 %), vitamin
D supplementation improved physical functioning. Twelve
studies included participants with either low 25(OH)D or
poor physical function at baseline, and physical function
improved in seven (58 %) of these studies. Only one study
included persons with both low 25(OH)D and poor phys-
ical function [31] and this trial observed a significant im-
provement of physical performance.
In conclusion, the effect of vitamin D supplementation
seems more pronounced in persons with low 25(OH)D
levels, depressive symptoms and poor physical function
at baseline. However, RCTs that specifically included par-
ticipants with these characteristics are scarce. Furthermore,
to the best of our knowledge, no studies have examined
the effect of vitamin D supplementation on the combin-
ation of mental and physical functioning, despite the fact
that these are interrelated concepts.
The current RCT aims to fill this knowledge gap by
investigating whether older adults at high risk for poor
mental and physical health can benefit from supplementa-
tion with vitamin D. Primarily, the D-Vitaal trial examines
whether vitamin D supplementation improves depressive
symptoms, functional limitations and physical performance
in persons with low 25(OH)D levels, clinically relevant
depressive symptoms and functional limitations. Other,
secondary health outcomes are assessed as well, such as
incident MDD [32], anxiety [33], health-related quality
of life [34, 35] and cognitive functioning [36]. In addition,
it will be investigated whether vitamin D supplementation
is a cost-effective strategy for the above-mentioned aims.
If proven effective, vitamin D supplementation can easily
be implemented in the primary care setting as a simple
and safe strategy to prevent both mental and physical dis-
orders in the elderly population.
Methods/design
Design of the study
The D-Vitaal study is a randomized, double-blind, placebo-
controlled clinical trial that is carried out in the
Netherlands. This study examines the effect of a daily
dose of 1200 IU vitamin D3 versus placebo on depressive
symptoms, functional limitations and physical perform-
ance. We included 155 participants aged 60–80 years. The
duration of the intervention is one year. The D-Vitaal trial
was approved by the Medical Ethics Committee of the VU
University Medical Centre Amsterdam and is registered
with the Netherlands Trial Register under NTR3845. The
D-Vitaal study adheres to the CONSORT guidelines for
randomized controlled trials.
Participants
Potential participants were screened for presence of clin-
ically relevant depressive symptoms, functional limitations
and low serum 25(OH)D levels (≤50 or ≤70 nmol/L in
winter (October-March) and summer (April-September),
respectively). In this way, we recruited a vulnerable
population at high risk of subsequent mental and physical
function decline. As severe 25(OH)D deficiency can be as-
sociated with bone disease [37], persons with 25(OH)D
levels of <15 nmol/L were excluded and referred to their
GP for treatment. In addition, persons with a current
MDD diagnosis were excluded, as the aim of this study is
to prevent depression. Furthermore, persons who use anti-
depressant medication were excluded at screening because
of possible interference of antidepressants with the effect
of vitamin D on depressive symptoms. Persons with suffi-
cient concentrations of 25(OH)D (>50 or >70 nmol/L in
winter and summer, respectively) were also excluded, as it
was expected that the effect of supplementation in these
persons would be negligible. The summer/winter cut-off
difference of 20 nmol/L was based on the observation by
Van Schoor et al. that the seasonal variation of vitamin
D levels in two cohorts of Dutch older persons was 14–
24 nmol/L [38]. The Health Council of the Netherlands
advises a supplement of 800 IU/day vitamin D for insti-
tutionalized persons [39]. Therefore, only community
dwelling persons were included in the trial. Table 3 lists
the inclusion and exclusion criteria of the D-Vitaal study.
All participants provided written informed consent prior
to the start of the intervention.
Recruitment and setting
The D-Vitaal study is carried out in Amsterdam and sur-
rounding municipalities in the Netherlands. Both urban
and rural areas were included. The majority of the partici-
pants was recruited through municipality registries. Munici-
palities in the surroundings of Amsterdam provided the
addresses of inhabitants in the age range of 60–80 years.
These persons received an information brochure about the
study by mail. In addition, advertisement posters and infor-
mation leaflets were distributed in community centres.
About 20 % of participants was recruited through general
practitioners (GPs) in Amsterdam. Using a standardized
search in their electronic medical records, the GPs selected
eligible patients between 60–80 years. These patients re-
ceived a letter from their GP to draw their attention to the
study. Finally, excluded participants of a previous clinical
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trial [40] who had indicated to be interested in contribut-
ing to future research, were invited to participate in the
D-Vitaal study. Recruitment commenced in June 2013
and the inclusion was finalized in April 2015. Figure 2
shows a flow chart of the recruitment, selection and
randomization in the D-Vitaal study.
Screening phase
The screening phase of the D-Vitaal study included two
steps: a mailed questionnaire and a short interview includ-
ing a blood sample. The screening questionnaire assessed
presence of depressive symptoms (Centre of Epidemio-
logical Studies - Depression scale (CES-D) score of ≥16
Fig. 2 Recruitment, selection and randomization in the D-Vitaal study
Table 3 Inclusion and exclusion criteria of the D-Vitaal study
Inclusion criteria: Exclusion criteria:
- Men and women of ≥60 and ≤80 years - Presence of major depressive disorder at screening
- Presence of depressive symptoms (CES-D ≥16) - Use of antidepressant medication at screening
- Presence of ≥1 functional limitation - Presence of major life-threatening illness
- Serum 25(OH)D levels ≤50 (winter) or ≤70 (summer) nmol/L. - Vitamin D (>400 IU/day) or calcium (>1000mg/day) supplementation
- Ability to comply with the study protocol - Serum 25(OH)D levels <15 nmol/L.
- Living in an institution
CES-D: Centre of Epidemiological Studies Depression scale
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[41]) and functional limitations and was also used to ex-
clude persons who use antidepressant medication, vitamin
D >400 IU/day and/or calcium supplements >1000 mg/day.
For the first 12 participants, we used only the Functional
Limitations questionnaire of the Longitudinal Aging Study
Amsterdam (LASA-FL) [42] for the assessment of func-
tional limitations. A LASA-FL score of ≥1 indicates the
presence of functional limitations. However, this instrument
proved not sensitive enough for this study population, cre-
ating a large ceiling effect. Especially younger-old partici-
pants (e.g. persons in their early sixties) reported few or no
problems on this scale, as their level of general functioning
was still moderate to high. Therefore, we added the Physical
Functioning subscale of the Short Form-36 Health Survey
[43] (SF-36-PF) to the screening phase. The SF-36-PF
contains 10 items on physical functioning and assesses
a broader range of functional limitations. Having diffi-
culty with at least one of the items of the SF-36-PF was
regarded as presence of functional limitations. Persons
who were eligible according to the screening questionnaire
(presence of both depressive symptoms and functional lim-
itations) were invited for a screening visit where presence
of MDD was examined and a blood sample was drawn to
determine serum 25(OH)D levels.
Intervention and randomisation
Participants were randomly allocated with a 1:1 ratio to
one of two treatment groups: vitamin D3 (cholecalciferol)
1200 IU/day or placebo. Participants were stratified by sex
and women were stratified by age (60–70 years/71–80
years). An independent pharmacist prepared three ran-
domisation lists with computer-generated numbers using
block sizes of four.
The intervention group takes three tablets of 400 IU
vitamin D3 daily for a duration of 12 months. Based on
earlier research, the daily dose of 1200 IU will lead to
stable mean 25(OH)D levels of >80 nmol/L in the inter-
vention group, with 90 % of individual 25(OH)D levels
above 60 nmol/L within a few months [44, 45]. The pla-
cebo group receives identical tablets without vitamin
D and it is expected that this group maintains a mean
serum 25(OH)D level of about 45 nmol/L. Both the
vitamin D and placebo tablets were purchased from
Vemedia Manufacturing B.V., The Netherlands. The
tablets are supplied in vials of 100 tablets for 6 months,
600 tablets at a time. Participants are allowed to take a
(multi)vitamin D supplement with a maximum of 400 IU/
day in addition to the study tablets.
Co-intervention
Calcium positively influences the bioavailability of vitamin
D [46]. In addition, some effects of vitamin D may be
caused by increased calcium absorption. Therefore, all
participants were advised to use at least three dairy
consumptions daily to ensure adequate calcium intake
of about 1000 mg/day. Calcium intake was assessed with a
structured questionnaire during the screening phase. If
calcium intake was low (less than 2 dairy consumptions
per day), calcium tablets of 500 mg/day were prescribed to
these participants.
Study procedures
Face-to-face interviews take place at screening, baseline,
six and 12 months. The baseline visit was timed closely
after the screening phase. Shortly prior to the interviews,
participants are asked to complete a mailed questionnaire
to reduce interview time. Short telephone interviews
are conducted after two weeks, three and nine months
to check compliance and adverse events. Table 4 lists
all measurements and their time points of the D-Vitaal
study. Interviews and blood sampling are carried out by
trained researchers or research nurses and take place at
the participant’s home, at the VU University Medical
Center, or at local community medical centres. The Endo-
crine Laboratory of the VU University Medical Center
conducts the 25(OH)D determinations. Participants who
discontinue taking the study tablets for any reason are asked
to participate in the remaining follow-up measurements.
Any (serious) adverse events are carefully monitored.
Compliance
Compliance is checked by tablet count. To stimulate
compliance, participants are contacted by telephone (after
two weeks, three and nine months) and reminded at
follow-up visits. The ultimate compliance check is the
measurement of serum 25(OH)D after 6 months.
Outcomes
Primary outcomes
Depressive symptoms The CES-D [41] is used to meas-
ure differences in mean change of depressive symptoms
after 12 months between the two treatment groups. The
CES-D contains 20 items with a score range of 0–60.
Higher scores indicate more depressive symptoms. A
score of ≥16 is indicative of clinically relevant depressive
symptoms. The CES-D is a widely used instrument that
displays good psychometric properties in various elderly
populations [47].
Functional limitations The LASA-FL questionnaire
[42] includes six items assessing common daily activities:
climbing stairs, cutting toenails, walking 5 minutes out-
doors without resting, rising from a chair, dressing/
undressing oneself and using own or public transport. Par-
ticipants indicate whether they are able to perform these
activities without difficulty, with some difficulty, with much
difficulty, only with help, or not at all. The instrument can
be scored in two ways: by determining the amount of
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functional limitations (score range 0–6, with higher scores
indicating presence of more functional limitations) and
the degree of functional limitations (score range 0–24,
with higher scores indicating more severe functional
limitations). The LASA-FL is used to measure differences
in mean change of the amount and degree of functional
limitations after 12 months between the two treatment
groups.
Physical performance A modified version of the Short
Physical Performance Battery (SPPB) [26, 48] is used to
determine differences in mean change of objective phys-
ical performance between the treatment groups after
12 months. The SPPB includes a walking test (walking 3
meters, turning 180° and walking 3 meters back as fast
as possible), a chair stands test (standing up from a chair
without using hands five times as fast as possible) and a
Table 4 Assessed domains, instruments and their time points in the D-Vitaal study
Time point
Domain Instrument Screening T0 (baseline) T1 (6 months) T2 (12 months)
Primary outcome variables:
Depressive symptoms CES-D X X X X
Functional Limitations LASA-FL X X X X
SF-36 PCS Partly X X X
Physical performance SPPB X X X
Secondary outcome variables:
Major depressive disorder CIDI X X X
Anxiety BAI X X X
Health-related quality of life SF-36 X X X
EQ-5D X X X
Cognition Stroop test X X X
Physical performance
Mobility TUG X X X
Hand grip strength Dynamometer X X X
Health care costs TiC-P X X X





Marital status X X X
Lifestyle
Smoking behaviour X X X
Alcohol consumption X X X
Physical activity LAPAQ X X X
Blood pressure Omron device X X X
Anthropometry
BMI Height, weight X X X
Waist and calf circumference Tape measure X X X
Chronic diseases 7 majors X X X
Medication and supplement use X X X
Predictors of vitamin D status X X X
Use of counselling X X X
CES-D: Centre of Epidemiological Studies Depression scale; LASA-FL: Longitudinal Aging Study Amsterdam Functional Limitations questionnaire; SF-36 PCS: Short
Form 36 Health Survey - Physical Component Summary score; SPPB: Short Physical Performance Battery; CIDI: Composite International Diagnostic Interview; BAI:
Beck Anxiety Inventory; EQ-5D: EuroQol 5 Dimensions; TUG: Timed Up-and-Go test; TiC-P: Trimbos and iMTA questionnaire on Costs associated with Psychiatric
illness; LAPAQ: Longitudinal Aging Study Amsterdam Physical Activity Questionnaire
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balance test (standing with feet in tandem stand (i.e.
standing with one foot in front of the other, with the
heel of one foot touching the toes of the other foot) for
up to 30 seconds). Participants can score 0–4 points for
each test, adding up to a maximum of 12 points, with
higher scores indicating better performance. Reliability
and validity of the SPPB are good [49].
Secondary outcomes
Incidence of MDD The depression-section of the DSM
IV-based Composite International Diagnostic Interview
(CIDI, version 2.1) [50] is used to assess presence of
MDD. At six and 12 months, the CIDI is administered if
a participant scores ≥16 on the CES-D.
Anxiety The Beck Anxiety Index (BAI) [51, 52] is a well-
validated questionnaire that contains 21 items measuring
anxiety symptoms that are relatively distinguishable from
depression symptoms.
Cognition Cognitive function is assessed with indicators
of information processing speed and executive function-
ing obtained from the Stroop-Colour Word Test [53].
Health-related quality of life Health-related quality of
life is measured with the EuroQol - 5 Dimensions (EQ-5D)
[54] and the SF-36 [43]. The EQ-5D is a utility instrument
that enables the calculation of Quality Adjusted Life Years
(QALY’s). The SF-36 Mental Component Summary score
(MCS) and Physical Component Summary score (PCS) are
used as a measure of mental and physical health-related
quality of life, respectively [43]. Both instruments are widely
used and well-validated in older populations [43, 55].
Timed Up-and-Go test With the Timed Up-And-Go
Test (TUG), functional mobility is assessed by asking the
participant to stand up from a standard chair, walk a 3
meter distance, turn, walk back to the chair and sit down
again [56].
Hand grip strength Hand grip strength is measured in
kilograms with a strain-gauged dynamometer (Takei
TKK 5401, Takei Scientific Instruments Co. Ltd.,
Japan). Participants are asked to apply maximum force
on the device while in a standing position. Grip strength
is measured twice for each hand, consecutively alternating
between both hands. The hand grip strength score is de-
rived by taking the mean of the highest score for each
hand.
Economic evaluation To evaluate whether vitamin D is
a cost-effective intervention for the prevention of depression
and poor physical function in older persons, an economic
evaluation will be performed. Dutch costing guidelines will
be used [57]. All relevant costs will be measured and valued,
including the costs of the vitamin D intervention. Health
care utilization is measured with the Trimbos and iMTA
questionnaire on Costs associated with Psychiatric illness
(TiC-P) [58]. Health care costs include costs of GP and
psychiatric care, ambulatory and outpatient hospital care,
physical therapists and home care. Costs of production
loss are not included, as the majority of the participants
does not have a paid job.
Possible covariables
Several variables are measured during the trial to check
for possible (chance-based) differences between the treat-
ment groups. Height and weight are measured with a cali-
brated stadiometer and scale, respectively. Body mass
index (BMI) is calculated by dividing weight (in kilograms)
by height2 (in meters). Waist and calf circumference is
assessed with a tape-measure. Blood pressure and pulse
are assessed twice with a three-minute interval using the
Omron M1 Plus device (Omron Healthcare Europe). The
date of the baseline interview is used to measure seasonal
variation of serum 25(OH)D levels [38]. Structured ques-
tionnaires assess age, gender, education level, marital
status, smoking behaviour, alcohol use, current medication
and supplement use, use of corticosteroids in the past
three months, chronic diseases, physical activity (walking,
cycling, gardening, household activities and sports [59],
vitamin D predictors (exposure to sunlight, skin pig-
mentation, consumption of fatty fish) [60] and use of
counselling.
Blood sampling and assessment of serum 25(OH)D
Blood samples are obtained in the morning by a trained
research nurse at screening and 6 months for measure-
ment of serum 25(OH)D. Participants are in a fasted state
with regard to dairy products. Serum 25(OH)D is deter-
mined using liquid chromatography followed by tandem
mass spectrometry [61]. At screening, 25(OH)D was deter-
mined immediately after blood sampling. The 25(OH)D
determinations of the 6-month blood samples will be car-
ried out at the end of the study, to ensure randomization
concealment. Serum, EDTA plasma and whole blood sam-
ples are stored frozen (−80 ° C) until determination and for
potential future biomarker and DNA research.
Power calculation
The primary outcomes of the D-Vitaal study are change
in depressive symptoms (CES-D score) and change in
physical functioning (functional limitations and physical
performance) after 12 months. In an RCT with a com-
parable population (older persons from the community
with depressive symptoms but no MDD), the mean
CES-D score was 26 (SD: 5.1) [62]. To detect a change
of 0.5 SD (i.e. 2.5 points change of CES-D score), a total
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of 40 subjects per group is needed, assuming a power of
80 %, a two-sided alpha of .05 and an intraclass correlation
coefficient (ICC) of .70 between baseline and follow-up
measurements.
The SPPB score ranges from 0 to 12. A change of one
point (SD: 1.5) is regarded as a meaningful change [63].
Assuming the same power, alpha and ICC as the CES-D
calculation, 22 participants per group are needed.
The LASA-FL questionnaire is scored in two ways: by
determining the amount (score range 0–6) and the degree
(score range 0–24) of functional limitations. A change of
one point in the amount of functional limitations can be
regarded as a meaningful change [64]. The SD was set on
1.7, based on analyses in the Longitudinal Aging Study
Amsterdam (LASA), a large prospective cohort study of
older persons. Assuming again the same power, alpha and
ICC as the previous calculations, at least 28 persons per
group should be included. For the degree of functional
limitations, no meaningful change data or RCTs could be
identified in the literature. Based on analyses in LASA, a
mean difference of 2 points can be expected, with an SD
of 4.5. For this outcome, 48 persons per group are needed,
using the same assumptions as indicated above. Consid-
ering an expected dropout of 25 % and uncertainty of the
25(OH)D assay, we aimed to include at least 70 partici-
pants per group, altogether at least 140 participants.
Data analysis
Baseline characteristics between treatment groups will be
compared using Pearson Chi-square tests, independent-
samples t-tests, one-way ANOVAs, or non-parametric
tests. Persons who drop out will be compared to persons
who complete the study. Skewed data will be transformed.
Data will be analysed according to the intention-to-treat
principle with longitudinal data analysis techniques (gen-
eralized estimating equation (GEE) analysis or mixed
model analysis) using SPSS (SPSS Inc. Chicago, IL, USA).
A double-sided p-value of .05 will be regarded as statisti-
cally significant. If needed, models will be adjusted for
relevant confounding variables. To investigate the inter-
relatedness of depressive symptoms and physical function-
ing, these variables will be added to each other’s effect
analysis in separate models. Effect modification will be in-
vestigated for age, gender and baseline serum 25(OH)D
levels.
Per-protocol analyses will be performed as a secondary
analysis with participants who were compliant with the
study protocol (≥80 % tablet intake). As a compliance
check, the improvement of vitamin D status - i.e. the
number of participants with serum 25(OH)D levels over
50, 60 and 75 nmol/L - will also be analysed in secondary
analyses. Finally, as a sensitivity analysis, it will be investi-
gated whether change in serum 25(OH)D is associated
with change in depressive symptoms, functional limitations
and physical performance over time in the total study sam-
ple (irrespective of treatment group).
The economic evaluation will be performed from a so-
cietal perspective with a time horizon of 12 months. The
analysis will be done according to the intention-to-treat
principle. Missing cost and effect data will be imputed
using multiple imputation according to the MICE algo-
rithm [65]. Bias-corrected and accelerated bootstrapping
with 5000 replications will be used to calculate 95 %
confidence intervals around the mean difference in
total costs between the two groups. Incremental cost-
effectiveness ratios (ICERs) will be calculated by divid-
ing the difference in mean total costs by the difference
in mean effects on the primary outcomes (depressive symp-
toms, functional limitations and physical performance) be-
tween the treatment groups. A cost-utility analysis will be
performed estimating the incremental costs per QALY
gained. Bootstrapping will be used to estimate the uncer-
tainty surrounding the ICERs, which will be graphically
presented on cost-effectiveness planes. Cost-effectiveness
acceptability curves and net monetary benefits will also be
calculated. Sensitivity analyses will be performed on the
most important and uncertain cost parameters.
Discussion
As depressive symptoms and poor physical functioning
are prevalent among older persons and cause significant
individual and societal burden [66], effective low-cost
prevention strategies are urgently needed. The D-Vitaal
study aims to examine whether vitamin D supplementa-
tion decreases depressive symptoms and functional limita-
tions and improves physical performance in older adults.
The majority of RCTs that examined vitamin D supple-
mentation included participants with adequate serum
25(OH)D levels and good mental and physical health,
which may explain the absence of effects of some previous
clinical trials in the field [12].
The D-Vitaal trial is innovative in several ways: it in-
cludes persons who may benefit most from the supple-
mentation: older persons with low serum 25(OH)D levels
and at high risk for developing poor mental and physical
health. Furthermore, the tight interrelationship between
depressive symptoms and physical functioning is taken
into account by targeting both concepts in one RCT.
Physical functioning is measured comprehensively with
both self-reported questionnaires and objective tests. Fi-
nally, MDD diagnosis is included as a secondary outcome
measure. This enables us to explore the effect of the vita-
min D supplementation on the development of MDD. To
our knowledge, this outcome has not been investigated
previously in an RCT [12].
It is more urgent to study the effects of vitamin D sup-
plementation in persons with inadequate vitamin D levels
than to examine whether there are any additional effects
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of supplementation above normal ranges [67]. The
amount of supplementation (1200 IU/ day) used in the
D-Vitaal study is a moderate dose, but sufficient to cor-
rect for deficiency and obtain an adequate vitamin D
status [44, 45].
If the results of the D-Vitaal trial indicate that vitamin
D supplementation is effective in reducing depressive
symptoms and improving physical functioning in older
adults, vitamin D can be an efficient intervention that
targets two prevalent adverse health conditions simul-
taneously. The economic evaluation will provide evidence
on the cost-effectiveness of the intervention. As vitamin D
supplementation is inexpensive and displays minimal side
effects, opportunities for implementation in the pri-
mary care setting seem promising. The first results of
the D-Vitaal study are expected in 2016.
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